Bristol-Myers Squibb | BMY

Stock Price
44.70
Daily Change
-4.16 -8.51%
Monthly
-14.94%
Yearly
-34.28%
Q2 Forecast
53.25
Peers Price Chg Day Year Date
ABBV AbbVie 167.20 -0.81 -0.48% 3.34% Apr/25
ABT Abbott 106.90 -0.06 -0.06% -1.70% Apr/25
ALKS ALKERMES 24.44 0.37 1.52% -13.90% Apr/25
AMGN Amgen 269.42 -3.72 -1.36% 12.82% Apr/25
AZN AstraZeneca 12,007.00 -19.00 -0.16% 1.79% Apr/26
BIIB Biogen 202.49 0.36 0.18% -29.70% Apr/25
BMY Bristol-Myers Squibb 44.70 -4.16 -8.51% -34.28% Apr/25
CTLT Catalent 55.80 -0.14 -0.25% 31.73% Apr/25
GILD Gilead Sciences 65.07 -1.83 -2.73% -22.30% Apr/25
GSK GlaxoSmithKline 1,639.00 -1.50 -0.09% 14.06% Apr/26
JNJ J&J 146.84 -1.73 -1.16% -9.70% Apr/25
LLY Eli Lilly 729.01 -8.11 -1.11% 93.75% Apr/25
MDT Medtronic 79.06 -1.21 -1.50% -12.13% Apr/25
MRK Merck 130.49 3.59 2.83% 15.04% Apr/25
NOVN Novartis 89.48 -0.52 -0.58% -2.05% Apr/26
PBH Prestige Brands 70.14 0.01 0.01% 14.81% Apr/25
PFE Pfizer 25.26 -0.97 -3.69% -34.61% Apr/25
PRGO Perrigo 31.26 0.03 0.10% -13.28% Apr/25
RDY Drreddys Laboratories 74.02 3.10 4.37% 24.47% Apr/25
REGN Regeneron Pharmaceuticals 906.54 -16.99 -1.87% 16.52% Apr/25
ROG Roche Holding 219.50 0.70 0.32% -20.53% Apr/26
SAN Sanofi 90.12 -1.51 -1.64% -11.50% Apr/26
SNY Sanofi 49.33 2.77 5.95% -12.26% Apr/25
UTHR United Therapeutics 235.98 -1.02 -0.43% 4.48% Apr/25
ZTS Zoetis 153.44 2.51 1.66% -11.28% Apr/25

Indexes Price Day Year Date
SPX US500 5083 -23.21 -0.46% 22.90% Apr/26

Bristol-Myers Squibb traded at $44.70 this Thursday April 25th, decreasing $4.16 or 8.51 percent since the previous trading session. Looking back, over the last four weeks, Bristol-Myers Squibb lost 14.94 percent. Over the last 12 months, its price fell by 34.28 percent. Looking ahead, we forecast Bristol-Myers Squibb to be priced at 53.25 by the end of this quarter and at 50.26 in one year, according to Trading Economics global macro models projections and analysts expectations.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.